Shares of Danaher Corporation (NYSE:DHR) have been given a consensus rating of “Buy” by the nineteen analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, thirteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $93.55.
A number of brokerages recently commented on DHR. Robert W. Baird increased their price target on Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Credit Suisse Group increased their price target on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Morgan Stanley increased their price target on Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 20th. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a report on Thursday, October 5th. Finally, J P Morgan Chase & Co restated an “overweight” rating and set a $95.00 price objective on shares of Danaher in a research note on Friday, September 8th.
In other news, CFO Daniel L. Comas sold 88,184 shares of the stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.02, for a total transaction of $8,026,507.68. Following the sale, the chief financial officer now directly owns 227,816 shares in the company, valued at approximately $20,735,812.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the sale, the chief executive officer now owns 271,737 shares in the company, valued at $25,173,715.68. The disclosure for this sale can be found here. Insiders have sold a total of 273,810 shares of company stock worth $25,218,813 over the last quarter. Insiders own 12.20% of the company’s stock.
Shares of Danaher (NYSE DHR) traded up $0.03 on Monday, reaching $93.21. The company had a trading volume of 1,813,928 shares, compared to its average volume of 2,618,758. The stock has a market capitalization of $64,816.49, a P/E ratio of 23.95, a P/E/G ratio of 2.22 and a beta of 1.02. Danaher has a 1 year low of $77.52 and a 1 year high of $94.82. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00.
Danaher (NYSE:DHR) last issued its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. The firm had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. Danaher had a return on equity of 11.29% and a net margin of 13.36%. Danaher’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.87 earnings per share. sell-side analysts anticipate that Danaher will post 3.99 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be given a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date is Thursday, December 28th. Danaher’s payout ratio is 16.52%.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.